Search

Your search keyword '"Larocca, Alessandra"' showing total 634 results
Start Over Author "Larocca, Alessandra"
634 results on '"Larocca, Alessandra"'

1. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

Author

Bandini, Cecilia, Mereu, Elisabetta, Paradzik, Tina, Labrador, Maria, Maccagno, Monica, Cumerlato, Michela, Oreglia, Federico, Prever, Lorenzo, Manicardi, Veronica, Taiana, Elisa, Ronchetti, Domenica, D’Agostino, Mattia, Gay, Francesca, Larocca, Alessandra, Besse, Lenka, Merlo, Giorgio Roberto, Hirsch, Emilio, Ciarrocchi, Alessia, Inghirami, Giorgio, Neri, Antonino, and Piva, Roberto

Published
2023
Full Text
View/download PDF

4. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Author

Terpos, Evangelos, Mikhael, Joseph, Hajek, Roman, Chari, Ajai, Zweegman, Sonja, Lee, Hans C, Mateos, María-Victoria, Larocca, Alessandra, Ramasamy, Karthik, Kaiser, Martin, Cook, Gordon, Weisel, Katja C, Costello, Caitlin L, Elliott, Jennifer, Palumbo, Antonio, and Usmani, Saad Z

Subjects
Comparative Effectiveness Research, Health Services, Rare Diseases, Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Hematology, Orphan Drug, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Agents, Clinical Trials, Phase III as Topic, Disease Management, Humans, Multiple Myeloma, Quality of Life, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis
Abstract

Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the 'efficacy' of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual's composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting.

Published
2021

5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

6. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Author

Mateos, Maria Victoria, primary, Weisel, Katja, additional, Terpos, Evangelos, additional, Delimpasi, Sossana, additional, Kastritis, Efstathios, additional, Zamagni, Elena, additional, Delforge, Michel, additional, Ocio, Enrique, additional, Katodritou, Eirini, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Leleu, Xavier, additional, Otero, Paula Rodriguez, additional, Schjesvold, Fredik, additional, Cavo, Michele, additional, and Dimopoulos, Meletios A., additional

Published
2024
Full Text
View/download PDF

7. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators:A subgroup analysis from the OCEAN study

Author

Schjesvold, Fredrik H., Ludwig, Heinz, Mateos, Maria Victoria, Larocca, Alessandra, Abdulhaq, Haifaa, Norin, Stefan, Thuresson, Marcus, Bakker, Nicolaas A., Richardson, Paul G., Sonneveld, Pieter, Schjesvold, Fredrik H., Ludwig, Heinz, Mateos, Maria Victoria, Larocca, Alessandra, Abdulhaq, Haifaa, Norin, Stefan, Thuresson, Marcus, Bakker, Nicolaas A., Richardson, Paul G., and Sonneveld, Pieter

Abstract

Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS), but not overall survival (OS), versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma in the OCEAN study. Time to progression (TTP) <36 months after a prior autologous stem cell transplantation (ASCT) was a negative prognostic factor for OS with melflufen. This post hoc exploratory analysis evaluated patients refractory to prior alkylators (e.g., cyclophosphamide and melphalan) in OCEAN. In 153 patients refractory to prior alkylators (melflufen, n = 78; pomalidomide, n = 75), the melflufen and pomalidomide arms had similar median PFS (5.6 months [95% CI, 4.2–8.3] vs. 4.7 months [95% CI, 3.1–7.3]; hazard ratio [HR], 0.92 [95% CI, 0.63–1.33]) and OS (23.4 months [95% CI, 14.4–31.7] vs. 20.0 months [95% CI, 12.0–28.7]; HR, 0.92 [95% CI, 0.62–1.38]). Among alkylator-refractory patients with a TTP ≥ 36 months after a prior ASCT or no prior ASCT (melflufen, n = 54; pomalidomide, n = 53), the observed median PFS and OS were longer in the melflufen arm than the pomalidomide arm. The safety profile of melflufen was consistent with previous reports. These results suggest that melflufen is safe and effective in patients with alkylator-refractory disease, suggesting differentiated activity from other alkylators.

Published
2024

8. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.

Author

Ziccheddu, Bachisio, Giannotta, Claudia, D'Agostino, Mattia, Bertuglia, Giuseppe, Saraci, Elona, Oliva, Stefania, Genuardi, Elisa, Papadimitriou, Marios, Diamond, Benjamin, Corradini, Paolo, Coffey, David, Landgren, Ola, Bolli, Niccolò, Bruno, Benedetto, Boccadoro, Mario, Massaia, Massimo, Maura, Francesco, and Larocca, Alessandra

Subjects
REGULATORY T cells, WHOLE genome sequencing, T-cell exhaustion, KILLER cells, MULTIPLE myeloma
Abstract

Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However, a large fraction of patients inevitably relapse. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). We conducted an integrated analysis using whole-genome sequencing (WGS) and flow cytometry in patients with RRMM. WGS before and after treatment pinpointed genomic drivers associated with early progression, including RPL5 loss, APOBEC mutagenesis, and gain of function structural variants involving MYC and chromothripsis. Flow cytometry on 202 blood samples, collected every 3 months until progression for 31 patients, revealed distinct immune changes significantly impacting clinical outcomes. Progressing patients exhibited significant depletion of CD38-positive NK cells, persistence of T-cell exhaustion, and reduced depletion of regulatory T cells over time. These findings underscore the influence of immune composition and daratumumab-induced immune changes in promoting MM resistance. Integrating genomics and flow cytometry unveiled associations between adverse genomic features and immune patterns. Overall, this study sheds light on the intricate interplay between genomic complexity and the immune microenvironment driving resistance to Dara-Rd in patients with RRMM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma

Author

Ziccheddu, Bachisio, primary, Giannotta, Claudia, additional, D’Agostino, Mattia, additional, Bertuglia, Giuseppe, additional, Saraci, Elona, additional, Oliva, Stefania, additional, Genuardi, Elisa, additional, Papadimitriou, Marios, additional, Diamond, Benjamin, additional, Corradini, Paolo, additional, Coffey, David, additional, Landgren, Ola, additional, Bolli, Niccolò, additional, Bruno, Benedetto, additional, Boccadoro, Mario, additional, Massaia, Massimo, additional, Maura, Francesco, additional, and Larocca, Alessandra, additional

Published
2023
Full Text
View/download PDF

11. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

Author

Mina, Roberto, Falcone, Antonietta Pia, Bringhen, Sara, Liberati, Anna Marina, Pescosta, Norbert, Petrucci, Maria Teresa, Ciccone, Giovannino, Capra, Andrea, Patriarca, Francesca, Rota-Scalabrini, Delia, Bonello, Francesca, Musolino, Caterina, Cea, Michele, Zambello, Renato, Tacchetti, Paola, Belotti, Angelo, Cellini, Claudia, Paris, Laura, Grasso, Mariella, Aquino, Sara, De Paoli, Lorenzo, De Sabbata, Giovanni, Ballanti, Stelvio, Offidani, Massimo, Boccadoro, Mario, Monaco, Federico, Corradini, Paolo, and Larocca, Alessandra

Published
2021
Full Text
View/download PDF

16. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

17. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

18. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Akay, Olga Meltem, Amin, Bipinkumar, Anagnostopoulos, Achilleas, Anderson, Larry, Anttila, Pekka, Araujo, Carla, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Benboubker, Lotfi, Ben-Yehuda, Dina, Bladé, Joan, Blau, Igor Wolfgang, Boccia, Ralph, Burke, Lillian, Byeff, Peter, Cascavilla, Nicola, Cavo, Michele, Chantry, Andrew, Charles, Yen, Chaudhry, Arvind, Corso, Alessandro, Coyne, Mark, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Di Raimondo, Francesco, Dürig, Jan, Engelhardt, Monika, Escoffre-Barbe, Martine, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gay, Julie, Gisslinger, Heinz, Goldschmidt, Hartmut, Goncalves, Cristina, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Hayden, Patrick, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Honkalehto, Kirsti, Huben, Marianne, Huffman, John, Hunter, Hannah, Hus, Marek, Jagasia, Madan, Jagganath, Sundar, Janakiram, Murali, Jaiyesimi, Ishmael, Jenner, Matthew, João, Cristina, Johnson, Peter, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Kanate, Abraham, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Krauth, Maria-Theresa, Kuriakose, Phillip, Larocca, Alessandra, Lauri, Birgitta, Leleu, Xavier, Lucio, Paulo, Luppi, Mario, Mangiacavalli, Silvia, Mariette, Clara, Matsue, Kosei, Mellqvist, Ulf-Henri, Mendeleeva, Larisa, Meshad, Michael, Miller, Carole, Mohrbacher, Ann, Moreau, Philippe, Morelli, Anna Maria, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Öngören Aydin, Seniz, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pati, Asmin, Pavic, Michel, Pegourie, Brigitte, Pehlivan, Mustafa, Pierola, Ana Alfonso, Plesner, Torben, Pluta, Andrzej, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Sati, Hamdi, Selleri, Carmine, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Sonmez, Mehmet, Stone, Chester, Streetly, Matthew, Suzuki, Kenshi, Taetle, Raymond, Tafuri, Agostino, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Vidito, Sarah, Viterbo, Luisa, Vural, Filiz, Wang, Xiang Sean, Yağci, Munci, Yee, Andrew, Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, and Dimopoulos, Meletios

Published
2019
Full Text
View/download PDF

20. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.

Author

Schjesvold, Fredrik H., Ludwig, Heinz, Mateos, Maria‐Victoria, Larocca, Alessandra, Abdulhaq, Haifaa, Norin, Stefan, Thuresson, Marcus, Bakker, Nicolaas A., Richardson, Paul G., and Sonneveld, Pieter

Subjects
MULTIPLE myeloma, STEM cell transplantation, REFRACTORY materials, SUBGROUP analysis (Experimental design), OCEAN
Abstract

Melphalan flufenamide (melflufen), a first‐in‐class alkylating peptide‐drug conjugate, plus dexamethasone demonstrated superior progression‐free survival (PFS), but not overall survival (OS), versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma in the OCEAN study. Time to progression (TTP) <36 months after a prior autologous stem cell transplantation (ASCT) was a negative prognostic factor for OS with melflufen. This post hoc exploratory analysis evaluated patients refractory to prior alkylators (e.g., cyclophosphamide and melphalan) in OCEAN. In 153 patients refractory to prior alkylators (melflufen, n = 78; pomalidomide, n = 75), the melflufen and pomalidomide arms had similar median PFS (5.6 months [95% CI, 4.2–8.3] vs. 4.7 months [95% CI, 3.1–7.3]; hazard ratio [HR], 0.92 [95% CI, 0.63–1.33]) and OS (23.4 months [95% CI, 14.4–31.7] vs. 20.0 months [95% CI, 12.0–28.7]; HR, 0.92 [95% CI, 0.62–1.38]). Among alkylator‐refractory patients with a TTP ≥ 36 months after a prior ASCT or no prior ASCT (melflufen, n = 54; pomalidomide, n = 53), the observed median PFS and OS were longer in the melflufen arm than the pomalidomide arm. The safety profile of melflufen was consistent with previous reports. These results suggest that melflufen is safe and effective in patients with alkylator‐refractory disease, suggesting differentiated activity from other alkylators. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. P-392 Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with daratumumab-len-dex

Author

Giannotta, Claudia, primary, Ziccheddu, Bachisio, additional, D'Agostino, Mattia, additional, Bertuglia, Giuseppe, additional, Saraci, Elona, additional, Oliva, Stefania, additional, Bolli, Niccolo', additional, Landgren, Ola, additional, Bruno, Benedetto, additional, Boccadoro, Mario, additional, Maura, Francesco, additional, Massaia, Massimo, additional, and Larocca, Alessandra, additional

Published
2023
Full Text
View/download PDF

22. OA-44 Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial

Author

Beksac, Meral, primary, Richardson, Paul, additional, Oriol, Albert, additional, Lindsay, Jindriska, additional, Schjesvold, Fredrik, additional, Galli, Monica, additional, Yağci, Münci, additional, Larocca, Alessandra, additional, Weisel, Katja, additional, Yu, Xin, additional, Donahue, Cynthia, additional, Acosta, Jorge, additional, Peluso, Teresa, additional, and Dimopoulos, Meletios, additional

Published
2023
Full Text
View/download PDF

23. P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE

Author

D’agostino, Mattia, primary, Bringhen, Sara, additional, Giuliani, Nicola, additional, Antonioli, Elisabetta, additional, Zambello, Renato, additional, Cattel, Francesco, additional, Ria, Roberto, additional, Allegra, Alessandro, additional, Leonardi, Giovanna, additional, Belotti, Angelo, additional, Galieni, Piero, additional, Margiotta-Casaluci, Gloria, additional, Cantonetti, Maria, additional, Cotugno, Valentina, additional, Gamberi, Barbara, additional, Pane, Fabrizio, additional, Liberati, Anna Marina, additional, Tosi, Patrizia, additional, Cavalli, Maide Maria, additional, Mannina, Donato, additional, Benevolo, Giulia, additional, Mangiacavalli, Silvia, additional, Evangelista, Andrea, additional, Ciccone, Giovannino, additional, Boccadoro, Mario, additional, Bruno, Benedetto, additional, and Larocca, Alessandra, additional

Published
2023
Full Text
View/download PDF

24. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

Author

Bringhen, Sara, Offidani, Massimo, Palmieri, Salvatore, Pisani, Francesco, Rizzi, Rita, Spada, Stefano, Evangelista, Andrea, Di Renzo, Nicola, Musto, Pellegrino, Marcatti, Magda, Vallone, Roberto, Storti, Sergio, Bernardini, Annalisa, Centurioni, Riccardo, Aitini, Enrico, Palmas, Angelo, Annibali, Ombretta, Angelucci, Emanuele, Ferrando, Paola, Baraldi, Anna, Rocco, Stefano, Andriani, Alessandro, Siniscalchi, Agostina, De Stefano, Valerio, Meneghini, Vittorio, Palumbo, Antonio, Grammatico, Sara, Boccadoro, Mario, and Larocca, Alessandra

Published
2018
Full Text
View/download PDF

25. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

Author

D’Agostino, Mattia, Larocca, Alessandra, Offidani, Massimo, Liberati, Anna Marina, Gaidano, Gianluca, Petrucci, Maria Teresa, Derudas, Daniele, Capra, Andrea, Zambello, Renato, Cascavilla, Nicola, de Fabritiis, Paolo, Innao, Vanessa, Bonello, Francesca, Patriarca, Francesca, Benevolo, Giulia, Giuliani, Nicola, Aitoro, Gabriele, Guglielmelli, Tommasina, Di Raimondo, Francesco, Corradini, Paolo, Musto, Pellegrino, Hájek, Roman, Sonneveld, Pieter, Boccadoro, Mario, and Bringhen, Sara

Published
2021
Full Text
View/download PDF

26. Lysin (K)-Specific Demethylase 1 Inhibition Enhances Proteasome Inhibitor Response and Overcomes Drug Resistance in Multiple Myeloma

Author

Bandini, Cecilia, primary, Mereu, Elisabetta, additional, Paradzik, Tina, additional, Labrador, Maria, additional, Maccagno, Monica, additional, Cumerlato, Michela, additional, Oreglia, Federico, additional, Prever, Lorenzo, additional, Manicardi, Veronica, additional, Taiana, Elisa, additional, Ronchetti, Domenica, additional, D'Agostino, Mattia, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Merlo, Giorgio, additional, Hirsch, Emilio, additional, Ciarrocchi, Alessia, additional, Inghirami, Giorgio, additional, Neri, Antonino, additional, and Piva, Roberto, additional

Published
2023
Full Text
View/download PDF

29. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Author

Mina, Roberto, Belotti, Angelo, Petrucci, Maria Teresa, Zambello, Renato, Capra, Andrea, Di Lullo, Giacomo, Ronconi, Sonia, Pescosta, Norbert, Grasso, Mariella, Monaco, Federico, Cellini, Claudia, Gobbi, Marco, Ballanti, Stelvio, de Fabritiis, Paolo, Mosca-Siez, Maria Letizia, Marchetti, Monia, Liberati, Anna Marina, Offidani, Massimo, Giuliani, Nicola, Ria, Roberto, Musto, Pellegrino, Romano, Alessandra, Sonneveld, Pieter, Boccadoro, Mario, and Larocca, Alessandra

Published
2020
Full Text
View/download PDF

30. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Author

Saltarella, Ilaria, Morabito, Fortunato, Giuliani, Nicola, Terragna, Carolina, Omedè, Paola, Palumbo, Antonio, Bringhen, Sara, De Paoli, Lorenzo, Martino, Enrica, Larocca, Alessandra, Offidani, Massimo, Patriarca, Francesca, Nozzoli, Chiara, Guglielmelli, Tommasina, Benevolo, Giulia, Callea, Vincenzo, Baldini, Luca, Grasso, Mariella, Leonardi, Giovanna, Rizzo, Manuela, Falcone, Antonietta Pia, Gottardi, Daniela, Montefusco, Vittorio, Musto, Pellegrino, Petrucci, Maria Teresa, Dammacco, Franco, Boccadoro, Mario, Vacca, Angelo, and Ria, Roberto

Published
2019
Full Text
View/download PDF

31. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Author

Larocca, Alessandra, Dold, Sandra Maria, Zweegman, Sonja, Terpos, Evangelos, Wäsch, Ralph, D’Agostino, Mattia, Scheubeck, Sophia, Goldschmidt, Hartmut, Gay, Francesca, Cavo, Michele, Ludwig, Heinz, Straka, Christian, Bringhen, Sara, Auner, Holger W., Caers, Jo, Gramatzki, Martin, Offidani, Massimo, Dimopoulos, Meletios A., Einsele, Hermann, Boccadoro, Mario, Sonneveld, Pieter, and Engelhardt, Monika

Published
2018
Full Text
View/download PDF

32. Supplementary Appendix from Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

Author

D'Agostino, Mattia, primary, Zaccaria, Gian Maria, primary, Ziccheddu, Bachisio, primary, Rustad, Even H., primary, Genuardi, Elisa, primary, Capra, Andrea, primary, Oliva, Stefania, primary, Auclair, Daniel, primary, Yesil, Jennifer, primary, Colucci, Paola, primary, Keats, Jonathan J., primary, Gambella, Manuela, primary, Bringhen, Sara, primary, Larocca, Alessandra, primary, Boccadoro, Mario, primary, Bolli, Niccolò, primary, Maura, Francesco, primary, and Gay, Francesca, primary

Published
2023
Full Text
View/download PDF

36. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Author

Palumbo, Antonio, Bringhen, Sara, Mateos, Maria-Victoria, Larocca, Alessandra, Facon, Thierry, Kumar, Shaji K., Offidani, Massimo, McCarthy, Philip, Evangelista, Andrea, Lonial, Sagar, Zweegman, Sonja, Musto, Pellegrino, Terpos, Evangelos, Belch, Andrew, Hajek, Roman, Ludwig, Heinz, Stewart, A. Keith, Moreau, Philippe, Anderson, Kenneth, Einsele, Hermann, Durie, Brian.G.M., Dimopoulos, Meletios A., Landgren, Ola, San Miguel, Jesus F., Richardson, Paul, Sonneveld, Pieter, and Rajkumar, S. Vincent

Published
2015
Full Text
View/download PDF

37. Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status

Author

Giannotta, Claudia, primary, Castella, Barbara, additional, Tripoli, Ezio, additional, Grimaldi, Daniele, additional, Avonto, Ilaria, additional, D’Agostino, Mattia, additional, Larocca, Alessandra, additional, Kopecka, Joanna, additional, Grasso, Mariella, additional, Riganti, Chiara, additional, and Massaia, Massimo, additional

Published
2022
Full Text
View/download PDF

39. Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Author

Kaiser, Martin F., primary, Sonneveld, Pieter, additional, Cairns, David, additional, Raab, Marc S, additional, Larocca, Alessandra, additional, Brown, Sarah R, additional, Baertsch, Marc-A., additional, Li, Cong, additional, Musto, Pellegrino, additional, Yong, Kwee, additional, Mai, Elias K, additional, Capra, Andrea, additional, Cook, Gordon, additional, Goldschmidt, Hartmut, additional, Boccadoro, Mario, additional, Jackson, Graham, additional, Weinhold, Niels, additional, and Gay, Francesca, additional

Published
2022
Full Text
View/download PDF

40. Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Author

Bringhen, Sara, primary, D'Agostino, Mattia, additional, Giuliani, Nicola, additional, Attucci, Irene, additional, Zambello, Renato, additional, Ronconi, Sonia, additional, Vincelli, Iolanda Donatella, additional, Allegra, Alessandro, additional, Leonardi, Giovanna, additional, Rossi, Giuseppe, additional, Cattel, Francesco, additional, Capra, Andrea, additional, Galieni, Piero, additional, Lombardo, Alessandra, additional, Bonello, Francesca, additional, Tosi, Patrizia, additional, Cavalli, Maide Maria, additional, Sciorsi, Elisa, additional, Mannina, Donato, additional, Ria, Roberto, additional, Patriarca, Francesca, additional, Cavo, Michele, additional, Mangiacavalli, Silvia, additional, Benevolo, Giulia, additional, Evangelista, Andrea, additional, Boccadoro, Mario, additional, Bruno, Benedetto, additional, and Larocca, Alessandra, additional

Published
2022
Full Text
View/download PDF

42. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Author

D'Agostino, Mattia, primary, Cairns, David A., additional, Lahuerta, Juan José, additional, Wester, Ruth, additional, Bertsch, Uta, additional, Waage, Anders, additional, Zamagni, Elena, additional, Mateos, María-Victoria, additional, Dall'Olio, Daniele, additional, van de Donk, Niels W.C.J., additional, Jackson, Graham, additional, Rocchi, Serena, additional, Salwender, Hans, additional, Bladé Creixenti, Joan, additional, van der Holt, Bronno, additional, Castellani, Gastone, additional, Bonello, Francesca, additional, Capra, Andrea, additional, Mai, Elias K., additional, Dürig, Jan, additional, Gay, Francesca, additional, Zweegman, Sonja, additional, Cavo, Michele, additional, Kaiser, Martin F., additional, Goldschmidt, Hartmut, additional, Hernández Rivas, Jesús María, additional, Larocca, Alessandra, additional, Cook, Gordon, additional, San-Miguel, Jesús F., additional, Boccadoro, Mario, additional, and Sonneveld, Pieter, additional

Published
2022
Full Text
View/download PDF

43. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study

Author

Efficace, Fabio, primary, Gaidano, Gianluca, additional, Petrucci, Maria Teresa, additional, Niscola, Pasquale, additional, Cottone, Francesco, additional, Codeluppi, Katia, additional, Antonioli, Elisabetta, additional, Tafuri, Agostino, additional, Larocca, Alessandra, additional, Potenza, Leonardo, additional, Fozza, Claudio, additional, Pastore, Domenico, additional, Rigolin, Gian Matteo, additional, Offidani, Massimo, additional, Romano, Alessandra, additional, Kyriakou, Charalampia, additional, Cascavilla, Nicola, additional, Gozzetti, Alessandro, additional, Derudas, Daniele, additional, Vignetti, Marco, additional, and Cavo, Michele, additional

Published
2022
Full Text
View/download PDF

44. P-191: The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review

Author

Mian, Hira, primary, McCurdy, Arleigh, additional, Giri, Smith, additional, Grant, Shakira, additional, Rochwerg, Bram, additional, Winks, Erica, additional, Rosko, Ashley, additional, Engelhardt, Monika, additional, Pawlyn, Charlotte, additional, Cook, Gordon, additional, Jackson, Graham, additional, Brighen, Sara, additional, Facon, Thierry, additional, Larocca, Alessandra, additional, Zweegman, Sonja, additional, and Wildes, Tanya, additional

Published
2022
Full Text
View/download PDF

45. P-253: Impact of adjusting bortezomib dose in the pomalidomide, bortezomib, and dexamethasone (PVd) combination: a post hoc analysis of the OPTIMISMM study

Author

Larocca, Alessandra, primary, Weisel, Katja, additional, Galli, Monica, additional, Oriol, Albert, additional, Facon, Thierry, additional, Dhanasiri, Sujith, additional, Hong, Kevin, additional, Gentili, Christian, additional, Mu, Yutian, additional, Guo, Shien, additional, Schjesvold, Fredrik, additional, Dimopoulos, Meletios A., additional, and Richardson, Paul, additional

Published
2022
Full Text
View/download PDF

46. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Author

Palumbo, Antonio, Bringhen, Sara, Kumar, Shaji K, Lupparelli, Giulia, Usmani, Saad, Waage, Anders, Larocca, Alessandra, van der Holt, Bronno, Musto, Pellegrino, Offidani, Massimo, Petrucci, Maria T, Evangelista, Andrea, Zweegman, Sonja, Nooka, Ajay K, Spencer, Andrew, Dimopoulos, Meletios A, Hajek, Roman, Cavo, Michele, Richardson, Paul, Lonial, Sagar, Ciccone, Giovannino, Boccadoro, Mario, Anderson, Kenneth, Barlogie, Bart, Sonneveld, Pieter, and McCarthy, Philip L

Published
2014
Full Text
View/download PDF

49. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

Author

De Stefano, Valerio, primary, Larocca, Alessandra, additional, Carpenedo, Monica, additional, Cavo, Michele, additional, Di Raimondo, Francesco, additional, Falanga, Anna, additional, Offidani, Massimo, additional, Petrucci, Maria Teresa, additional, Ruggeri, Marco, additional, Santi, Roberto Mario, additional, and Barosi, Giovanni, additional

Published
2022
Full Text
View/download PDF

50. Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty.

Author

Oriol Rocafiguera, Albert, primary, Dimopoulos, Meletios A., additional, Schjesvold, Fredrik, additional, Beksac, Meral, additional, Yagci, Münci, additional, Larocca, Alessandra, additional, Guo, Shien, additional, Mu, Yutian, additional, Hong, Kevin, additional, Dhanasiri, Sujith, additional, Richardson, Paul G., additional, and Weisel, Katja, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results